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QUALITATIVE STUDY OF A PRIMARY CARE-BASED HEPATITIS C 
TREATMENT PROGRAM AT A SAFETY-NET HOSPITAL  
MAGDALENA BUCZEK 
ABSTRACT 
Introduction:  Mortality associated with hepatitis C virus (HCV) infection is 
increasing, yet only a small percentage of HCV-infected individuals are aware of 
their infections, complete treatment, and achieve a cure, defined as a sustained 
virologic response.  In March 2015, the Section of General Internal Medicine at 
Boston Medical Center (BMC), New England’s largest safety-net hospital, 
implemented the Adult Primary Care HCV Treatment and Triage Program to 
increase access to treatment.  We are unaware of prior studies that have 
explored a pharmacist-centered primary care-based HCV treatment model in the 
era of newer direct-acting antiviral (DAA) medications.  
Objectives: To gain a deeper understanding of the roles of each program staff 
member, as well as an understanding of how primary care providers (PCPs) who 
refer patients to the program perceive and interact with the program. Such an 
understanding will help promote implementation and dissemination of the 
program. 
Methods:  We conducted in-depth semi-structured interviews with six staff 
members and with five PCPs in the Section of General Internal Medicine at BMC 
who refer patients to the program.  We asked staff members about their roles 
and their perception of the program’s impact on patient linkage to HCV treatment.  
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We probed PCPs about their experiences with HCV screening, referral, and 
follow-up processes, and differences in accessing HCV treatment for their 
patients prior to and following the implementation of the program.  We 
audiotaped and transcribed interviews, and identified major themes through 
qualitative analysis.   
Results:  We identified five major themes that characterize how the HCV 
treatment program delivers care: 1) efficiency (“So here I feel like…they get 
evaluated…they get treated.  Boom, it’s done”); 2) clear and open 
communication (“…one of the strengths of our program is that we have…a lot of 
direct contact with patients…”); 3) personalized medicine (“…I've set up the pill 
box for them [patients]…we tailor it to whatever they need”); 4) high patient 
engagement (“So if I get a referral for a patient…I call the patient three times.  If I 
haven’t heard from the patient…I send them a letter and I tell the PCP”); 5) 
patient empowerment through education (“I think patient education is the best 
thing…if the patient is involved then… they’ll do what they need to do”).  
Additionally, the public health social worker and the pharmacist play key roles in 
the program.  The social worker supports patients throughout treatment and 
addresses psychosocial barriers to treatment engagement (“I had a patient…who 
stopped taking his medication because his apartment was infested with bed 
bugs…[Social worker] got the patient furniture for free and got an 
exterminator…”).  The pharmacist provides medication management during face-
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to-face patient visits (“…I go over everything imaginable...proper 
adherence…adverse effects, interactions…”).  
Conclusions:  The HCV treatment program at BMC is a promising model to 
deliver HCV treatment to urban, underserved patient populations.  Our findings 
suggest that public health social workers and pharmacists may be one approach 
to increasing access to HCV treatment in primary care settings in the era of DAA 
medications.  Further study of the program’s efficacy in improving HCV outcomes 
is warranted. 
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INTRODUCTION 
Hepatitis C Virus (HCV) Infection – A Growing Problem 
 
HCV is a primarily blood borne pathogen that infects the liver.  The single-
stranded ribonucleic acid (RNA) virus is prone to error during viral replication,1 
and thus there exist six major genotypes and multiple subtypes within each 
genotype.2  Genotype 1 is the most prevalent genotype, accounting for 83.4 
million cases (46.2%) globally.3  In the United States, genotype 1 is the most 
common, accounting for 75.52% of cases, and genotypes 2 and 3 account for 
12.46% and 10.36% of cases respectively.  Genotypes 4-6 each account for 
<1.1% of cases.3     
HCV is primarily transmitted through percutaneous methods.  Common 
parenteral means of HCV transmission include the sharing of injection equipment 
by injection drug users (IDUs), the inadequate sterilization of medical equipment, 
and needle injuries in health care settings.4  About 15-25% of individuals with 
HCV infection clear the virus without treatment.  The remaining 75-85% of HCV-
infected individuals develop chronic infections.5  Acute HCV infection is mostly 
asymptomatic, and thus infections are rarely treated during this stage.  Chronic 
HCV infection is also usually asymptomatic until symptoms appear as a result of 
liver decompensation.6  Cirrhosis, the irreversible loss of liver cells and 
subsequent liver scarring, can lead to end-stage liver disease, hepatocellular 
carcinoma, and death if left untreated.4  HCV-related end-stage liver disease is 
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the leading indication for liver transplantation among adults in the United States, 
accounting for more than 30% of liver transplant cases.7  
An estimated 4.6 million people in the United States are HCV antibody-
positive, indicating they have a past or current HCV infection.  Of these, an 
estimated 3.5 million people are HCV RNA-positive, indicating they have a 
chronic HCV infection.8  Furthermore, mortality rates associated with HCV 
infection are growing.  Between 1999-2007, while deaths associated with human 
immunodeficiency virus (HIV) infection saw an age-adjusted annual decrease of 
.21 deaths per 100,000 people, deaths associated with HCV infection saw an 
age-adjusted annual increase of .18 deaths per 100,000 people.9  Another report 
noted an age-adjusted annual increase in HCV-related deaths of .14 deaths per 
100,000 people from 2003 to 2013.10  Meanwhile, the rate decreased by .34 
deaths per 100,000 people for a conglomerate of 60 infectious diseases over the 
same time period.10    
HCV infection rates are not consistent across subgroups of the United 
States population.  For example, the HCV antibody prevalence in adults born 
between 1945-1965 is 3.25%, which is five times higher than among adults born 
in any other year.11  Three-fourths of all chronic HCV infections are among adults 
in this birth cohort.11  Thus, a 2012 recommendation from the Centers for 
Disease Control and Prevention states that patients in the 1945-1965 birth cohort 
with no previous assessment of HCV risk should receive one-time HCV testing.12  
Additionally, previous HCV infection rate estimates may have been an 
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underestimate due to the omission of several vulnerable populations in sampling.  
Underrepresented groups that are at increased risk of HCV infection include 
individuals who are incarcerated, experiencing homelessness, and hospitalized, 
among others.8  The weighted average HCV seroprevalence rates across several 
studies for these three groups were 23.1%, 32.1%, and 15.6% respectively,8 
compared to the 1.0% rate in the general population.13  It is imperative to target 
high-risk populations for HCV screening and treatment to yield high cure rates.     
Today there exists a HCV treatment cascade of care in which a small 
percentage of HCV-infected individuals complete treatment and achieve 
sustained virologic response (SVR).  SVR is defined as the absence of 
detectable levels of viral RNA in the blood either 12 or 24 weeks after treatment 
completion.14,15,16  For example, a retrospective cohort study at BMC found that 
17% of patients with detectable viremia initiated HCV treatment between 2005-
2011.17  Additionally, only 1% of patients who engaged in HCV care in the same 
time period completed all five HCV quality indicators of care defined by the 
Centers for Medicare and Medicaid Services.17  Between 2014-2015, only 21.3% 
of individuals in the 1945-1965 birth cohort were screened for HCV at urban and 
suburban internal medicine clinics in the Henry Ford Health System based in 
Detroit, Michigan.18  Of the patients who tested positive, only 30% completed 
treatment.18  Other analyses have described similar drop-offs between the 
proportion of patients who are diagnosed with HCV infection and those who 
complete treatment and achieve SVR.19,20  
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HCV Treatment in the Interferon Era 
 
The history of HCV treatment and the strides made by the pharmaceutical 
and medical communities over the past few decades give context for low HCV 
linkage to care rates.  Interferon (IFN)-based treatments were the standard of 
care for HCV genotype 1 from 1991 – 2013.21  The original standard IFN 
treatment regimen was administered as an injection three times per week for six 
months, and resulted in SVR rates of 6% for HCV genotype 1.21,22  In 1998, the 
United States Food and Drug Administration (FDA) approved an IFN and ribavirin 
(RBV)23 combination and SVR rates for HCV genotype 1 increased to 32%.21  
Between 2001-2002, the FDA approved two pegylated interferon (peg-IFN) 
therapies,24,25 and when combined with RBV, SVR rates for HCV genotype 1 
increased to 43%.21   
IFN-based therapies were suboptimal on several counts.  First, SVR rates 
after therapy completion were low.  Second, side effects were frequent and 
harsh, making treatment completion difficult.  Common side effects of peg-IFN 
with RBV include fatigue, mild fevers, nausea, and coughing.26  The treatment 
regimen can potentially exacerbate or initiate depression and other psychiatric 
symptoms.26  IFN can induce neutropenia, a low count of a type of white blood 
cell called a neutrophil.22  Neutropenia in some patients can increase risk of 
bacterial infections.  RBV can also cause hemolytic anemia.23  Third, medication 
administration was complex, lengthy, and uncomfortable.  Peg-IFN came as a 
pen injection system or as a prefilled syringe for subcutaneous injection once 
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weekly.26  Medication injection was intimidating for patients and a potential trigger 
for IDUs in recovery. Additionally, treatment duration was lengthy, with the 
regimen lasting 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3.26  
Due to serious side effects, low medication efficacy, and inconvenient methods of 
medication administration, patients were not motivated to begin treatment, and 
providers were not eager to refer patients for treatment.  
Advent of Direct-Acting Antivirals (DAAs) 
In 2011, the FDA approved the first direct-acting antivirals (DAAs) in 
combination with peg-IFN and RBV for treatment of HCV genotype 1.  DAAs act 
directly on the viral life cycle and inhibit viral production.14   For example, 
telaprevir (Incivek)27 and boceprevir (Victrelis)28 are both NS3/4A protease 
inhibitors; they inhibit the enzyme NS3/4A protease that is involved in post-
translational processing of proteins.14  In contrast, IFN acts on the immune 
system.14  Telaprevir and boceprevir, in combination with peg-IFN and RBV, 
increased SVR rates to 70% for HCV genotype 1.21  In 2013, the FDA approved 
two other DAAs, also in combination with peg-IFN and RBV.  Simeprevir 
(Olysio)29 and sofosbuvir (Sovaldi)30 increased SVR rates for HCV genotype 1 
treatment–naïve patients (those who had never previously undergone HCV 
treatment) to 80% and 90%, respectively.21  DAAs presented new side effects in 
addition to those associated with peg-IFN and RBV, namely skin reactions and 
dysgeusia, a distortion in the sense of taste.21   
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Starting in 2014, the FDA began approving IFN-free HCV DAA therapies.  
Side effects drastically diminished without the IFN, and the number of treatment 
options for all genotypes increased.  These medications include 
ledipasvir/sofosbuvir (Harvoni)31 and ombitasvir/paritaprevir/ritonavir + dasabuvir 
(Viekira Pak)32 approved in 2014, daclatasvir (Daklinza)33 + sofosbuvir approved 
in 2015, and elbasvir/grazoprevir (Zepatier)34 approved in 2016.  Additionally, 
sofosbuvir/velpatasvir (Epclusa)35 is the first regimen indicated to treat HCV 
genotypes 1-6, and SVR rates reach 95-100% across the six genotypes.21  
Treatment adherence is eased since IFN-free DAA therapies are taken orally 
instead of as injections, and treatment duration is eight or twelve weeks as 
opposed to the 24 or 48 weeks for IFN-based therapies.  One exception is that 
treatment-experienced patients (those who have previously undergone HCV 
treatment) with cirrhosis may have to take the oral agents for 24 weeks.36  
Although barriers to treatment access associated with DAA medications exist, 
such as the high costs of the medications and the changing insurance 
requirements for prior authorizations (approvals from health plans to cover an 
ordered prescription), the improvements in the treatment process itself are 
substantial.     
The advent of oral, DAA medications has improved adherence to HCV 
treatment by easing side effects, improving medication administration methods, 
and decreasing treatment duration.  HCV treatment is also a cost-effective 
decision for the United States health care system.37,38  With such treatment 
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enhancements, it is critical that DAA medications be accessible to HCV-infected 
patients.  
Primary Care’s Role in Increasing HCV Treatment Accessibility  
 
Although oral IFN-free DAA therapies have improved medication 
adherence and treatment efficacy, the HCV treatment process continues to be 
complex and lengthy.  Daily adherence and regular lab monitoring are needed, 
and substance use should be limited.  Drug-drug interactions need to be 
monitored, especially given a high prevalence of chronic diseases39 and 
increasing polypharmacy in the United States.40  Additionally, many barriers to 
accessing HCV treatment still exist at the patient, provider, and system levels.  
Patient-level barriers include substance use,41,42,43 unstable housing,44 
inadequate social support,45,46 poor treatment literacy,41,44,46,47,48 stigma,41,43 
transportation logistics to distant medical facilities,41 low patient motivation,44 and 
physical and psychological comorbidities.42,44  Providers may also not have time 
to address or assess HCV infection.46  A system-level barrier includes long 
appointment wait times at specialty clinics.42,46  There is a need to support 
patients through the complex treatment schedule and to address barriers to care.  
One approach is to treat HCV infection in primary care as opposed to in specialty 
clinics.  
Why might HCV treatment in primary care provide support for patients and 
reduce barriers to care?  First, there is an insufficient supply of clinicians to treat 
HCV infection, and long appointment wait times to see such clinicians are 
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associated with high no-show rates.42,49,50  HCV treatment provided by primary 
care providers (PCPs) increases the number of providers who deliver care and 
thus may reduce appointment wait times.  Second, treatment in a new specialty 
clinic where patients are unfamiliar with staff and clinic procedures may be a 
deterrent to seeking care.  On the other hand, the familiarity of a primary care 
clinic may facilitate patient education, counseling, and general support.  
Oftentimes patients with HCV have co-morbidities such as diabetes, and health 
behaviors such as tobacco and other substance use that can be more effectively 
monitored and treated at the same location as their HCV treatment.  Third, many 
patients with HCV infection do not have a consistent home address, phone 
number, or mode of transportation.  The lack of dependable communication and 
transportation makes it difficult to establish contact between a patient and a new 
clinic.  The primary care setting may enable face-to-face engagement about HCV 
treatment in a location that is familiar to patients.   
In March 2017, we conducted a literature search to identify studies that 
assessed HCV treatment in primary care.  We aimed to better understand the 
models through which primary care settings deliver HCV treatment.  We only 
included studies that incorporated HCV treatment into a primary care setting; 
studies that solely integrated HCV screening or linkage-to-care efforts were 
excluded.  We found twelve studies published between 2006-2017 that met our 
criteria.  One-third (4/12) of programs were geared specifically towards 
increasing HCV treatment access among IDUs.51,52,53,54  Two studies had primary 
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outcomes other than increasing HCV treatment access in primary care: one 
focused on increasing HCV screening and linkage-to-care rates,55 and a second 
focused on the implementation of a weekly HCV treatment support group.51  
Nonetheless, both studies incorporated HCV treatment into a primary care 
setting and were thus included in our review.  Finally, one study incorporated 
HCV treatment into four federally-qualified health centers (FQHCs), as well as six 
syringe exchange programs (SEPs) and two collocated FQHCs and SEPs.55  The 
health care settings in all twelve studies served high-risk and underserved 
populations.    
We found no published studies of treatment programs that were 
implemented solely in the era of newer oral agents.  All twelve studies utilized at 
least some IFN-based treatment.  Ten studies utilized peg-IFN and RBV 
exclusively.  One study utilized triple therapy exclusively (telaprevir or boceprevir 
in combination with peg-IFN and RBV),56 and another study utilized triple therapy 
in 26.4% of patients and peg-IFN and RBV regimens in the remaining cases.57  
Eight programs were implemented in urban settings, two in rural settings,57,58 and 
two in mixed (urban, suburban, and/or rural) settings.59,60  Two of the studies in 
urban settings occurred at the same site,56,61 and the two programs utilized in 
rural areas both incorporated Project Extension for Community Healthcare 
Outcomes (ECHO) clinics.57,58  The Project ECHO model utilizes 
videoconferencing technology for specialists to train PCPs in HCV treatment, and 
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it has been widely accepted as a successful model for HCV treatment expansion 
into primary care.58  
Two-thirds (8/12) of studies utilized patient navigation.  Patient navigation 
connects and integrates healthcare systems so that patients move swiftly through 
a complex continuum of care.62  Patient navigation tasks may include, but are not 
limited to: communicating with patients, referring patients to social and addiction 
support programs, and organizing referrals, insurance logistics, transportation, 
and appointment escorts.62  Patient navigation is a useful method for ensuring 
treatment adherence in a vulnerable patient population facing significant barriers 
to care.  Although a majority of programs utilized patient navigation in their 
models, its implementation looked different from program to program.  For 
example, three programs assigned patient navigation tasks to clinical staff, such 
as registered nurses (RNs)52,58,60 and medical assistants (MAs).58  Another study 
utilized a counselor to provide practical and therapeutic support to patients.54  
Four other studies used HCV patient navigators,55,56,57,61 but none specified a 
public health social worker in the role of a patient navigator.  Finally, one-third 
(4/12) of studies did not mention a patient navigator role.51,53,59,63   
HCV-specific education or training for patient navigation was only 
specified in one of the eight studies, and it consisted of a five day training in a 
HCV-focused navigation curriculum (e.g. navigation protocols, data collection, 
expectations, data reporting, and caseload management).55  Interestingly, the 
three studies that implemented Project ECHO clinic sessions varied in their 
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patient navigation (one relied on the local health department or a HCV patient 
navigator in higher volume clinics depending on the state and need,57 one used a 
RN coordinator,60 and one used either a RN or MA coordinator58).  
One-third (4/12) of studies utilized a pharmacist as part of a 
multidisciplinary specialist team57,58 or a primary care HCV treatment team.60,63 
Multidisciplinary specialist teams served as resources and supports for PCPs 
implementing HCV treatment, such as those that provided guidance with 
videoconferencing technology in the Project ECHO clinics.  Multidisciplinary 
primary care HCV treatment teams determined treatment plans and delivered 
HCV care.  In one program, a pharmacist was part of the health center that 
implemented HCV treatment, but the paper did not specify a direct role for the 
pharmacist in the HCV treatment process.52  None of the studies ascribed a 
leading or managerial role in HCV treatment to the pharmacist.  Seven studies 
did not mention a pharmacist role.  
Pharmacist-provided treatment programs have effectively managed 
patients and their medications in chronic diseases such as diabetes,64 
hypertension,65,66,67 and high cholesterol.68  A few health systems have 
implemented pharmacist-provided medication management models for HCV 
treatment, but none as far as we know have been in primary care settings or 
have exclusively utilized IFN-free, DAA treatment regimens.  Rather, health 
systems implemented these models in specialty clinics and during the IFN 
era.69,70,71   
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The treatment models in the twelve studies reviewed here demonstrate 
that primary care centers are well positioned to play a major role in increasing 
access to HCV treatment, especially in more vulnerable populations.  As of 
March 2017, we are unaware of primary care-based HCV treatment programs 
that follow the model implemented at Boston Medical Center (BMC), namely that 
of a pharmacist-provided medication management program utilizing a public 
health social worker as a patient navigator in the era of DAA therapies.  The 
following section describes the HCV treatment program at BMC in more depth.   
Primary Care HCV Treatment Program at Boston Medical Center (BMC) 
 
The Adult Primary Care HCV Treatment and Triage Program was 
implemented in March 2015 in the Section of General Internal Medicine at BMC.  
The program was established in anticipation of a greater volume of patients 
expressing interest in HCV treatment following the advent of new, IFN-free, DAA 
medications.  The program is based on the Chronic Care Model (CCM), a 
multidimensional approach to improving chronic disease care in primary care.72  
Revenue generated from the 340B drug discount program supported the 
employment of a multidisciplinary HCV treatment delivery team and 
implementation of the program.  Under the 340B drug discount program, safety-
net providers purchase drugs from manufacturers at lower prices than the 
insurance reimbursements they receive, thus generating revenue when patients 
fill their prescriptions at safety-net setting pharmacies.73    
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Lasser et al. describe the structure of the primary care HCV treatment 
program at BMC.74  Briefly, the program utilizes the following staff members: a 
public health social worker (hereon called “case manager”); a pharmacist; a 
pharmacy technician; and general internists trained to treat HCV (hereon called 
“PCP treaters”).  As part of training, PCP treaters complete American Association 
for the Study of Liver Diseases online training modules and shadow a specialist 
physician who treats HCV-infected patients for one four-hour clinic session.75  
PCPs may consult specialist physicians for clinical backup by phone and 
electronic messaging.     
 The program receives referrals from several sources.  General internal 
medicine PCPs who are not trained to treat HCV (hereon called “referring PCPs”) 
refer patients to the program.  To aid referring PCPs in screening for HCV 
infection, the program implemented a “best practice alert” in the electronic health 
record (EHR) at BMC in April 2016.  This alert notifies providers to complete a 
one-time HCV test of patients in the 1945-1965 birth cohort.  The program also 
receives notifications of all positive HCV antibody results from the BMC 
laboratory and of HCV-infected patients who are not engaged in care from the 
BMC EHR.  Lastly, the program accepts peer referrals from community programs 
and referrals from the BMC Emergency Department (ED).   
 The case manager reviews charts of referred patients and reaches the 
following patients by phone call to schedule an initial appointment with a PCP 
treater: those who have active viremia, who are not connected to treatment, and 
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who do not have co-morbidities that would require specialty care.  Patients co-
infected with HIV are referred to infectious disease; patients with hepatitis B virus 
(HBV) infection, decompensated cirrhosis, or other significant comorbidities are 
referred to gastroenterology.  Throughout a patient’s participation in the program, 
the case manager delivers patient education, appointment reminders, and 
transportation assistance.  Additionally, the case manager maintains a log of 
patient interactions, outreach, and updates to help with patient management. 
 At the initial visit, the PCP treater assesses a patient’s HCV infection and 
gathers treatment and substance use history to gauge the risk of non-adherence 
to treatment and reinfection.  The PCP treater encourages avoidance of alcohol 
use and orders tests, including HCV genotype testing, complete blood count and 
INR, a complete metabolic panel, and hepatitis A virus (HAV), HBV, and HIV 
serology.  Additionally, the PCP treater places orders for the patient to obtain a 
FibroSure, FibroScan, and abdominal ultrasound.   
 Whenever possible, the PCP treater pages the case manager at the end 
of the appointment to do a warm handoff, a referral practice where a provider 
introduces a patient to another provider in-person.  The case manager’s office is 
located within the Adult Primary Care Clinic, and this proximity eases the 
patient’s transition to the program.  The case manager completes an intake 
assessment of the patient’s income, housing, mental health, substance use, and 
other social determinants of health.  The case manager follows up on any patient 
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needs through referrals to appropriate resources, such as job training, 
counseling, substance use treatment, and housing resources.  
 At the second visit with the PCP treater, the PCP treater and patient 
review the results of labs and other tests.  If patient readiness and motivation 
with regards to psychosocial factors and medication adherence are once again 
affirmed, the PCP treater prescribes the appropriate medication.  The patient 
also receives HAV and HBV vaccines as needed.   
 When the order for the HCV medication reaches the pharmacy, the 
pharmacy technician obtains the prior authorization (PA) for the treatment 
through the patient’s insurance company.  If the request for the PA is denied, the 
pharmacy technician in collaboration with the pharmacist collects relevant 
records to build a case for an appeal.  If the appeal is also denied, the case 
manager notifies the patient that they must wait one year before requesting a re-
evaluation.   
 Patients for whom treatment is approved meet with the pharmacist before 
initiating treatment.  The pharmacist teaches patients how to administer the 
medication, and about adverse effects and the importance of adherence.  The 
pharmacist contacts patients two weeks into their treatment course to check 
about adverse effects and to remind patients to pick up their medication refills.  
The pharmacist also meets with patients four weeks into the treatment course 
and at its completion.  At both of these visits, the pharmacist orders lab tests and 
assesses adherence and adverse effects.    
!!
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 Lastly, patients attend their final appointment with the PCP treater three 
months after their treatment completion.  At this visit, the PCP treater checks the 
HCV RNA to determine whether SVR is attained.74  Table 1 outlines the tasks of 
each of the program staff.  Figure 1 shows the flow of treatment in the program.  
Since the program implementation in March 2015, 46 patients attended the last 
appointment with the PCP treater and all achieved SVR. 
Table 1: Descriptions of staff roles in the primary care hepatitis C virus 
(HCV) treatment program at Boston Medical Center (BMC)  
Program staff role Role Description 
Case Manager  • Educates patients about HCV and the HCV treatment 
program 
• Schedules appointments with PCP treaters 
• Provides appointment reminder phone calls and 
addresses various psychosocial needs 
• Maintains patient log with communication and treatment 
details, from referral to discharge 
PCP Treater  • Visit #1: obtains infection, treatment, and substance use 
histories; orders lab and imaging tests 
• Visit #2: reviews test results, assesses motivation and 
readiness for treatment, prescribes indicated agent 
• Visit #3: checks HCV RNA to assess SVR attainment  
Pharmacist • Educates patients about medication administration, 
adverse effects, and importance of adherence 
• Assesses adverse effects and reminds patients about 
medication refills by phone call 
• Meets with patients during and at the end of treatment for 
lab testing and assessment of adherence and adverse 
effects 
Pharmacy 
Technician 
• Prepares PA paperwork 
• Appeals if PA is denied 
Abbreviations: Case Manager – public health social worker; PA – prior authorization; PCP – 
primary care provider; PCP treater – general internal medicine PCP trained to treat HCV; RNA – 
ribonucleic acid; SVR – sustained virologic response 
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Figure 1: Flow chart of the primary care hepatitis C virus (HCV) treatment program at Boston Medical 
Center (BMC) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: CM – case manager (public health social worker); ED – Emergency Department; EHR – electronic health record;  
PA – prior authorization; PCP – primary care provider; PCP treater – general internal medicine PCP trained to treat HCV; referring 
PCP – general internal medicine PCP who refers patients to the program; SVR – sustained virologic response 
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SPECIFIC AIMS AND OBJECTIVES 
The aims of this research are twofold.  The first objective is to gain a 
deeper understanding of the roles and activities of each program staff member in 
the primary care HCV treatment program in the Section of General Internal 
Medicine at BMC.  A greater knowledge of the team members’ tasks and the 
ways in which the team members collaborate will help facilitate the dissemination 
and implementation of the program in other primary care settings.  
The second objective is to gain an understanding of how PCPs who refer 
patients to the program perceive and interact with the program – its components 
and delivery of care.  Knowledge of referring PCPs’ experience of the program 
will also help facilitate the dissemination and implementation of the program in 
other primary care settings.   
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METHODS  
Setting 
The Adult Primary Care Practice is an accredited patient-centered medical 
home situated at BMC, New England’s largest safety-net hospital.  BMC serves a 
predominantly multicultural and low-income population.  Thirty-one percent of 
patients at BMC do not speak English as their primary language, and fifty-nine 
percent of patients are from under-served populations.76   
Participants 
 
Between March – June 2016, a research assistant (EAJ) invited staff 
members of the primary care HCV treatment program to participate in an open-
ended, semi-structured interview lasting 30-60 minutes.  Appendix A contains the 
study recruitment email used to reach staff members.  The research assistant 
conducted face-to-face, audio-recorded interviews in a confidential space with 
staff members who were willing to participate.  Six program staff members 
participated: the medical director, case manager, pharmacy technician, 
pharmacist, practice manager, and a PCP treater.  The medical director was also 
a PCP treater, and the other PCP treater interviewed was a suboxone prescriber 
in BMC’s Office Based Opioid Treatment with Buprenorphine (OBOT) Program.   
We also aimed to conduct semi-structured interviews with patients, in 
order to hear their perspective on engagement with the HCV treatment program.  
We particularly wished to hear from patients who were not engaging with the 
program: patients who we were unable to contact, who were missing their initial 
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visit with the PCP treater, or who were not following through on the steps towards 
treatment initiation.  We suspect that due to substance use and other chaotic life 
factors, it was difficult to reach these patients for an interview.  We amended the 
initial study protocol to conduct interviews with referring PCPs instead.  We 
believed that referring PCPs would have important insights on their encounters 
with the HCV treatment program that would help us more fully understand the 
program’s mechanisms.     
Between October – November 2016, the Principal Investigator (KEL) 
invited PCPs in the Section of General Internal Medicine at BMC to participate in 
a 30-minute open-ended, semi-structured interview.  Inclusion criteria required 
that PCPs had referred at least one patient to the primary care HCV treatment 
program and that their employment at BMC preceded the program 
implementation in March 2015.  Our goal was to interview referring PCPs who 
could compare their experiences in accessing HCV treatment for their patients 
before and after program implementation. Previously, the vast majority of PCPs 
referred their patients to a specialty clinic for HCV treatment, either 
gastroenterology or infectious disease.  One referring PCP was trained to treat 
HCV in primary care in the IFN era, but treated few patients.  Appendix B 
contains the email used to recruit referring PCPs.  A research assistant (MMB) 
administered the in-person, audio-recorded interview in a confidential space with 
those referring PCPs who wished to participate.  Five referring PCPs participated 
in the study out of nine who were emailed.   
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The Boston Medical Center/Boston University School of Medicine 
Institutional Review Board approved this protocol.  Written consent was obtained 
from all participating program staff members and referring PCPs.   
Data Collection 
 
Our aim with the staff member interviews was to explore staff perspectives 
on the effectiveness of the program and its various components, as well as 
barriers to its success.  Specifically, we were interested in how staff members 
perceive the program’s impact on patient linkage to HCV treatment, staff member 
roles, and resource utilization.  Our objective with the referring PCP interviews 
was to ascertain their experiences with HCV screening in their patient population, 
and with referral and follow-up processes of patients seeking HCV treatment.  
Additionally, we were seeking their perspective on differences in access to care 
for their patients from before the program implementation, when specialty clinic 
referrals were the norm, to after.  
The research team developed the program staff interview instrument, 
which is available in Appendix C.  In the first part of the interview, we asked 
participants to describe their role in the primary care HCV treatment program, 
their professional background, and any specialized training they may have 
received in HCV treatment.  We further probed about their roles by asking 
participants how they played a part in providing HCV treatment for a recent 
patient.  In the second part of the interview, we probed participants about any 
changes they have seen in processes, demand levels, and time frames 
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associated with access to care since the program implementation.  We also 
asked participants to describe changes in costs associated with program and 
patient management.  We utilized information gained from these probes in a 
budget impact analysis of the program, a separate project that also utilized 
information gleaned from the interview transcripts.  Towards the end of the 
interview, we asked participants to describe facilitators and barriers to the 
success of the program, and their viewpoints on strategies for promoting HCV 
care in primary care.   
The research team designed the referring PCP interview instrument by 
building on several themes identified in the staff interviews, such as procedural 
changes in accessing HCV treatment since the program implementation, barriers 
to care, and program staff roles.  The research team also sought insight from a 
medical sociologist with expertise in qualitative research (JAC).  Appendix D 
displays the referring PCP interview instrument.  During the in-person interview, 
we used probes as they fit most naturally to the flow of the conversation.  Initial 
questions asked referring PCPs to specify their role in and perception of the 
screening and referral processes prior to the program implementation.  We also 
probed participants about any barriers to care they were aware of prior to the 
program onset, specifically barriers at the patient, provider, and system levels.  
At the patient level, we were interested in barriers associated with medication 
side effects, substance use, and various social determinants of health, such as 
social and economic environments and transportation.  At the provider level, we 
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probed participants about remembering to screen patients for HCV, having the 
time to address HCV infection, and abstinence requirements for treatment.  At 
the system level, we probed participants about the logistics of making referrals to 
and scheduling appointments with specialty clinics, and about appointment wait 
times. 
The second part of the referring PCP interview instrument focused on 
HCV treatment access following the implementation of the primary care program.  
We asked referring PCPs about any changes in the screening and referral 
processes that they have experienced.  We also probed participants about their 
awareness of how different team members of the program (e.g. case manager, 
PCP treater, pharmacy technician, and pharmacist) support them and their 
patients.  We wanted to know how referring PCPs view the primary care 
program’s effectiveness in addressing the barriers they had named in the first 
half of the interview.  We also probed about any changes in their level of 
satisfaction with the accessibility and quality of treatment since the program 
implementation, and changes in the time frame from when they make a referral 
to when a patient begins treatment.  Finally, we probed participants about current 
barriers to patient engagement in treatment, and about a patient whom they had 
recently referred to the program. 
We concluded both the program staff interviews and the referring PCP 
interviews by asking demographic questions.  We maintained participants’ 
confidentiality with an anonymous numbering system for the audio recordings, 
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interview guides, and interview transcripts.  We offered program staff and 
referring PCPs a $25 gift card at the completion of the interview.   
Data Analysis 
 
Two research assistants (VT and MMB) transcribed audio-recordings 
verbatim.  One research assistant (MMB) imported interview transcripts into 
NVivo Software 10 for data management, coding, and analysis.77  Interviews and 
data analysis occurred concurrently, allowing for modifications to the interview 
guide and the order in which we delivered probes.  In accordance with grounded 
theory practice, a research assistant (MMB) initiated the coding process by 
identifying major categories of information within the raw text of the interview 
transcripts.78  We utilized the major categories of information to organize the data 
and to build coding frameworks.  We created some concrete codes to describe 
the HCV program components and processes.  We also applied thematic codes, 
like the perspectives of program staff and referring PCPs towards patient 
education, medications, and the role of the HCV program.  The research 
assistant (MMB) subsequently created subcategories around themes emerging 
from the data.78  Afterwards, we built narratives and relationships across the 
major themes around a core category.78  A research team read through the 
transcripts and met to discuss emerging codes and themes, allowing for an 
iterative approach to analysis of the interview data.    
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RESULTS 
Themes associated with treatment access in the primary care HCV 
treatment program  
 
Staff members of the primary care HCV treatment program and referring 
PCPs identified several themes associated with the program’s HCV treatment 
delivery to an urban, underserved population.  Themes include efficiency, clear 
and open communication, personalized medicine, high patient engagement, and 
patient empowerment through education.  Table 2 contains representative quotes 
from interview transcripts corresponding to each theme.   
Efficiency 
Efficiency in the HCV treatment program is identified as a faster treatment 
process and a smoother referral process.  The faster treatment process is due to 
a few factors: the case manager proactively engages the patient to schedule an 
initial appointment with the PCP treater; the pharmacy technician works diligently 
with insurance companies to obtain the PA for the prescribed agent; and PCP 
treaters increase the number of providers available to deliver HCV treatment.  
These factors may accelerate the linkage-to-care and treatment initiation 
processes.  Additionally, the referral logistics are smoother for patients and 
providers because they occur within the same clinic.  The case manager’s office 
is near the Adult Primary Care Clinic, and thus referring PCPs may engage in 
organic interactions with the case manager, such as paging her to do a warm 
handoff or knocking on her door to discuss a patient case.  Patients may also be 
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familiar with the location and processes of the primary care setting, which may 
further ease the transition.    
Clear and open communication 
Program staff and referring PCPs described clear and open 
communication at multiple levels within the program.  First, the staff 
communicate with referring PCPs through the EHR system about treatment 
updates and other medical issues.  One referring PCP mentioned how the case 
manager “sends me notes: ‘I was talking to so and so about their HCV and, by 
the way, they mentioned they need this, that, and the other thing.’”  The case 
manager connects back with referring PCPs to notify them of patients’ needs.   
Second, the program staff complete comprehensive documentation of 
outreach efforts and treatment updates.  The thorough notes allow referring 
PCPs to stay informed about a patient’s HCV treatment status.  Third, staff 
members communicate extensively with each other.  As a multidisciplinary 
treatment team, the staff support one another in contacting patients, working on 
PAs and appeals, providing medication management, and addressing other 
psychosocial needs.  One staff member explains that HCV treatment is 
challenging for one provider to deliver on his or her own, especially when each 
medication has a unique PA requirement and medication management is 
extensive.  The collaborative nature of the program helps because, “just having 
each individual that can assist, it just makes it go smoothly”.   
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Lastly, the program communicates frequently with patients, which allows 
the staff to provide support and to keep patients involved in their care.  
Specifically, the case manager and pharmacist play central roles.  The case 
manager engages in patient navigation, and the pharmacist facilitates detailed 
and consistent follow-up and teaching appointments with patients.  One referring 
PCP mentioned the following when she saw documentation of program staff 
placing phone calls to patients about medication refill reminders: “[the 
communication is] like all the things we wish would happen for every single other 
medication.  It seems like there’s that extra level of detail”.  
Personalized medicine 
 The program personalizes HCV treatment delivery in at least four ways.  
First, program staff ensure that treatment is conducive to a patient’s physical, 
social, and emotional environments.  For example, the pharmacist dispenses a 
week’s worth of medication to patients living in shelters if patients are 
uncomfortable holding on to all the medication.  In another instance, the 
pharmacy technician may have vulnerable patients sign a document that 
authorizes the pharmacy technician to be the designated representative for 
handling appeals with insurance companies on behalf of the patient.  A staff 
member explains the circumstances around such a decision:  
However, with Hepatitis C, we found that with managed care plans, they add an 
extra step…it requires the patient to consent with the insurance and there is also 
not usually a very direct phone number, a direct way of contacting the insurance 
to authorize this appeal. And because, you know, a lot of times there's language 
barriers or cultural barriers, or even just like, homelessness, no access to 
telephones. It’s hard for patients to know how and when to authorize an appeal. 
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So to bypass this we've had patients sign forms from the drug company [sic] that 
authorizes the liaison [pharmacy technician] or the provider as a designated 
representative to handle the appeal on behalf of the patient. 
  
In another example, the program accommodates HCV treatment delivery 
to alleviate patients’ discomfort and anxiety.  Program staff and referring PCPs 
perceived that patients are nervous about navigating the various steps in the 
HCV treatment process, such as finding the pharmacy to pick up their 
medications.  Getting stuck by a needle for lab tests may be a potential trigger for 
patients who are in recovery from intravenous (IV) drug use, and it may bring 
them discomfort.   Patients who are simultaneously receiving treatment for their 
opioid dependency in the OBOT program may experience apprehension 
associated with their recovery process.  In response, the pharmacy technician 
has the flexibility to show patients the way to the pharmacy or blood-draw station.  
This may seem like a small gesture, but it helps patients to progress from one 
step in the treatment process to the next.  The pharmacist and case manager 
may also provide added outreach and support for patients in substance use 
treatment.     
Second, the pharmacist sets up individualized reminders for patients to 
take medication daily, such as cell phone alarms or signs for a patient’s 
refrigerator.  Third, the pharmacist utilizes comprehensive teaching methods, 
such as pillboxes and teach-back methods, which are geared to each patient’s 
learning style and other health-related issues.  Health care providers use teach-
back methods to ensure that patients understand the communicated information 
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whereby they ask patients to “teach-back” the information.  Lastly, the case 
manager personalizes her communication to whichever format works best for 
patients, including text messaging, phone calls, and letters.  
High patient engagement 
 Program staff exert a high level of patient engagement through proactivity 
in connecting a patient to care, warm handoffs, and time investment when 
meeting with patients.  The case manager calls a patient three times and sends a 
letter in an attempt to schedule an intake appointment.  The warm handoff 
between the referring PCP or PCP treater and the case manager may alleviate 
patients’ apprehension about engaging unfamiliar health professionals and begin 
the trust-building process between the patient and the program.  The program 
staff also devote a significant amount of time when meeting with patients, which 
may provide patients with comfort and a safe space to acknowledge concerns 
about their HCV diagnosis.  Additionally, program staff and referring PCPs 
discussed how patients go through a cognitive journey of acceptance of their 
HCV diagnosis.  One referring PCP describes the cognitive process in this way:  
“…maybe it’s that model of acceptance, right, and they kind of go through denial 
and bargaining and all of the like, the seven stages before they get to acceptance 
and that may be what we’re seeing here.“  The time that program staff take to 
accompany patients as they accept their diagnosis may help patients initiate and 
follow through on treatment.  
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Patient empowerment through education 
 Patients may associate HCV treatment with the arduous and painful side 
effects of IFN-based medications and their low success rates in clearing the 
virus.  Some patients have watched friends or family members, or have 
themselves gone through the IFN-based treatments.  They have unpleasant and 
stress-inducing associations with the idea of HCV treatment.  Patients may be 
unaware of the fewer side effects, shorter treatment course, and higher SVR 
rates of the IFN-free, DAA therapies.  Staff members emphasize education about 
the responsibilities, timeline, and nature of HCV treatment during meetings with 
patients, including the difference between IFN-based treatments and DAA 
therapies.  One referring PCP describes the circumstance surrounding the 
education she provides to patients:  
…so the older, the people I would say who are in their fifties, sixties, seventies 
who have it, all know people who suffered or they themselves suffered through 
the treatment, so I’ve definitely, when I bring it up, they like jump to the ceiling 
and I have to talk them off the ceiling.  I mean, they really have post-traumatic 
stress disorder (PTSD) from these treatments.  
 
Knowledge about the program and treatment options alleviates patients’ 
stress and allows patients to make informed decisions regarding treatment. 
! 
31 
Table 2: Themes associated with hepatitis C virus (HCV) treatment access in the primary care HCV treatment program at 
Boston Medical Center (BMC) 
Program 
Theme 
Description Example from interview transcript 
Efficiency Faster treatment process P4: “So here I feel like it’s (clap, clap), they get evaluated, boom, boom (clap, 
clap), [Case Manager] sets them up, they get treated.  Boom, it’s done.” 
Smoother referral process 
due to proximity of program 
to primary care clinic 
P1: “Well, again, it just seems like it’s much smoother and it seems like, I 
mean, part of it is right there, so it is a lot easier for me to know what’s going 
on. And I’ve talked to [Case Manager] and asked her questions and if I have a 
question, I literally go knock on her door.” 
Clear and open 
communication 
Communication with 
referring PCPs via EHR 
system 
P2: “But she’s very good about sending messages in Epic [EHR] to say like, 
‘this patient didn’t show up, or this patient showed up and we’re going to 
begin treatment’, or whatever.  So I find that communication really helpful.”   
Thorough documentation of 
outreach efforts and 
treatment updates by staff 
P1: “…they’ve also done a good job of making it clear, which is just important 
from the perspective of the PCP in the chart, like this is the FibroScan, this is 
the genotype, you know, he has active HCV, he doesn’t qualify for treatment, 
we’re going to check this in 6 months, and then go from there, so it’s like 
really clear.”  
Communication between 
staff members 
S4: “I now have a lot of support with our pharmacy team, so [pharmacist] and 
then [pharmacy technician].  And they are super helpful and definitely a very 
important part of our team in terms of doing the other legs of what we do…we 
are constantly in communication, the three of us about what’s going on with 
patients and where they are… and we loop in the treater [PCP treater] as well 
so that we’re all kind of on the same page. There’s a lot of communication 
back and forth…” 
Communication with 
patients 
S4: “…I do think one of the strengths of our program is that we have the 
opportunity to have a lot of direct contact with patients, whether that’s in 
reminder calls or me spending a long time with patients, you know, after their 
provider visit, talking about HCV and explaining and kind of learning more 
about the patient and what their life is like and you know, I think a lot of that is 
really valuable…”  
Abbreviations: Case manager – public health social worker; EHR – electronic health record; PCP – primary care provider; PCP 
treater – general internal medicine PCP trained to treat HCV; referring PCP – general internal medicine PCP who refers patients to  
the program 
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(Table 2 Continued) 
Personalized 
medicine 
Accommodation of 
treatment access to 
patient’s physical, social, 
and emotional 
environments 
S2: “If they’re living in a shelter and they don’t feel comfortable with giving a 
full month of Harvoni to someone in the shelter then, you know, I can make a 
plan with the patient like, 'Hey, I’m going to bill the insurance for an entire 
month of drug but, you know, I’m going to count out seven, put it in a bottle, 
and we’re going to keep the stock in the pharmacy. You have seven.  Come 
back every week to see me and I’ll give you.'”  
Individualized reminders for 
patient to take medication 
daily 
S5: “Even we have patients with psych issues that I’ve sat down with them, 
I've set up the pill box for them and I've set an alarm on their cell phone for 
them so that they can like have so many different reminders. Like we tailor it 
to whatever they need. So like I’ve typed up a letter, I mean like a reminder 
sign in big letters that I've had patients put on their fridge or on their door. I 
don’t usually have a lot that miss.” 
Comprehensive teaching 
methods utilized to educate 
patient about the 
medication regimen and 
treatment process 
S5: “When we do the teaching, I sit down with them, I go over everything 
imaginable, like I go over how to take it, their proper adherence, you know 
what could happen if you don’t adhere to the medication, resistance, you 
know, avoiding alcohol and drugs…we talk about adverse effects. 
Interactions. I go over their med list and make sure things are up to date 
because I always do an interaction check before I see them…and then we go 
over the timeline, when they’re going to start, when they’re going to finish, 
when we’re going to see them, what the blood work means, everything.” 
Individualized 
communication with patient 
– texts, calls, letters 
S5: “[Case manager] plays a big part in that, calling and following up with 
them if they don't show up, calling them twice, sending them a letter, text 
messaging them with the SMS phone from here.” 
High patient 
engagement 
Proactive effort to keep 
patient connected to care 
S4: “So if I get a referral for a patient from a PCP, I call the patient three 
times. If I haven’t heard from the patient after the third phone call, I send them 
a letter and I tell the PCP. If the patient books an appointment during one of 
those first three phone calls, and no shows it, they get three calls following up 
to try and get them back in.  If they don’t answer, they get a letter. If they no 
show that first appointment and they get those three calls, and they set up a 
new appointment and no show the second one, I send them a letter. So 
there’s a lot of effort that goes in to trying to, you know, engage the patients.” 
Abbreviations: Case manager – public health social worker; PCP – primary care provider; SMS – short message service 
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    (Table 2 Continued) 
High patient 
engagement 
continued 
Warm handoff P1: “I think a lot of times if somebody is interested, at least that initial 
engagement, and I’m using that word in purpose, because I think there’s 
something about saying, ‘Hey, you’re interested in being treated for HCV?’, 
and like you, if [Case Manager] is usually there and has enough flexibility 
where I can walk the person down the hall, and if the patient has enough 
time, she’ll talk to them and…then you’re matching a name, I mean a face, 
with this new program, and so.”   
 
Time investment when 
meeting with patient 
S4: “So I spent a long time meeting with him. I talked with his [referring] PCP 
and I talked with…the doctor who treated him just to make sure that 
everybody was kind of on the same page. We talked about outpatient 
addiction resources…he came and met with me twice and that was like two 
weeks after his overdose…I wanted to make sure he had the resources that 
he needed. And so I think that was kind of a major role that I play with 
patients, is just trying to stay involved in their lives and make sure they know 
that I am here if they need resources.”  
 
Patient 
empowerment 
through 
education 
Education about the 
responsibilities, timeline, 
and nature of the treatment 
process 
S2: “I think patient education is the best thing. I think, you know, if patients 
want the treatment they'll get the treatment…I think educating the patients 
on the seriousness and how important even just the, how expensive…the 
treatment is…I think if the patient is involved then they'll show up for every 
appointment and they’ll do what they need to do.” 
 
Education about DAAs in 
contrast to IFN-based 
therapies 
P4: “And I’ve convinced a number of patients to go for treatment who, you 
know, were drug addicts for many years and who saw their young, you 
know, who are like in their sixties, fifties, sixties, seventies, who saw their 
peers die of HCV, you know, 10-15 years ago.  Or see them have horrible 
experiences with the [IFN-based] treatment, so they’re really prejudiced 
against it.” 
 
Abbreviations: Case manager – public health social worker; DAA – direct-acting antiviral; IFN – interferon; PCP – primary care 
provider; referring PCP – general internal medicine PCP who refers patients to the program 
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Primary care HCV treatment program staff roles 
 The four main staff members – the case manager, PCP treater, 
pharmacist, and pharmacy technician – undertake unique roles in the program.  
Perceptions of these roles provided by the staff and referring PCPs elucidate 
how staff members work together and what makes each role valuable.  Table 3 
summarizes these viewpoints and includes representative quotes from the 
interview transcripts.   
Case manager 
 The case manager plays a central role in connecting program staff with 
each other, program staff with patients, and the program to the primary care 
clinic of which it is a part.  The case manager is well informed about a patient’s 
needs and involved at every step of the treatment process.  The case manager is 
thus the central contact person for patients and other staff members, who are 
involved at different points of the treatment process.  She ensures that the 
patient keeps moving forward toward treatment completion.  The case manager 
describes her role in the following manner: 
[I am] the person who follows them [patients] through that whole process.  I have 
a lot of support from other team members, but I think I’m kind of the person that 
they can connect with through the whole thing because the other team members 
will come in at different places.   
 
Other staff members rely on the case manager as an extra resource, 
possibly due to the case manager’s broad involvement at every step of the HCV 
treatment process.  For example, they depend on the case manager to follow up 
with patients who miss an appointment or to inform patients of HCV treatment 
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logistics.  Referring PCPs also appreciate the case manager’s notifications about 
patients’ progress through treatment.  Referring PCPs are reassured that the 
case manager is following up with patients and relaying relevant information back 
to them.  The case manager’s role in facilitating communication between the staff 
and the referring PCPs may smooth the referral process and effectively embed 
the HCV treatment program in the primary care clinic.  
PCP treater 
 The program staff perceive the PCP treater to experience satisfaction in 
treating a disease that previously was not directly under a PCP’s purview.  
Because PCP treaters focus solely on the HCV infection during the appointment, 
the office visit seems less complicated than a regular PCP appointment where 
multiple chronic and acute issues are addressed simultaneously.  One PCP 
treater described delivering HCV treatment in the following manner: “…in a way, 
it has made my life as a PCP easier because a HCV visit is by definition easier 
than an average primary care visit because you’re only focusing on one 
issue…you’ll find that people treating HCV, they enjoy it, it’s satisfying for them.”  
Additionally, referring PCPs also appreciate the updates they receive from PCP 
treaters, who may serve as another link between the program and the primary 
care clinic in which it is housed.      
Pharmacist 
 Both staff members and referring PCPs recognize that the pharmacist 
delivers the time-consuming and labor-intensive components of HCV treatment 
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management, such as medication administration and follow up regarding adverse 
effects, medication adherence, and lab tests.  One PCP treater describes her 
perspective on the pharmacist’s role in the program:  
I think in general pharmacists do a lot more than is like kind of visible to us as 
physicians. And, because it makes sense that she does the counseling for it, 
adherence counseling, the way to take the medication, and then contacts you by 
phone and then also has them [patients] come in, I think every 4 weeks or 
something like that. 
   
The pharmacist’s role is significant for the implementation of the numerous 
treatment steps.    
Pharmacy technician 
 The pharmacy technician plays a critical role for treatment accessibility by 
obtaining the PA, without which patients cannot obtain their medications.  
Additionally, the pharmacy technician takes some workload off of referring PCPs 
and PCP treaters, who in other settings and for other tests/medications may 
need to be involved in the PA process.  Additionally, the partnership between the 
pharmacist and pharmacy technician is essential for the effectiveness of both 
roles.  The pharmacy technician relies on the pharmacist for guidance with more 
complex appeals.  The pharmacist relies on the pharmacy technician to handle 
communication with insurance companies, appointment scheduling, and follow-
up with patients about additional matters.  This working relationship ensures that 
medication regimens are not interrupted mid-treatment due to insurance or 
logistics issues and that the greatest number of patients can obtain PAs and 
begin treatment.  
! 
37 
Table 3: Perspectives on program staff roles in the primary care hepatitis C virus (HCV) treatment 
program at Boston Medical Center (BMC)  
Program staff 
role 
Staff view of role Example from interview transcript Referring PCP 
view of role 
Example from interview 
transcript 
Case 
Manager  
CM is an extra 
resource to rely on 
S5: “[CM] is always available to me 
as an extra resource, so if I 
needed her to reach out to that 
patient if I didn’t have the time or 
the resources to reach out to that 
patient, for additional adherence 
issues, she would certainly do so.” 
Communication 
from the CM is 
helpful  
P4: “[CM] is great, she’ll 
flag me if there’s other 
concerns that have come 
up in the HCV treatment, 
which are other medical or 
primary care concerns.” 
PCP treater  An appointment with 
a PCP treater is 
more straightforward 
than one with a PCP 
non-treater because 
only focused on one 
issue 
S3: “…it's actually very easy for 
them because it’s only one 
problem that they are addressing 
in the visit as opposed to trying to 
do diabetes, hypertension, and 
many, many other things that 
patients come up [with]. In their 
primary care visit, they just target 
HCV, which is a good thing for 
them because it’s a very focused 
visit. It’s kind of like being a 
specialist in a way.”  
Appreciation for 
updates from 
PCP treaters 
P5: “…they’ve been very 
good about writing me 
notes.  They’ll give me a 
brief note with an update.” 
Pharmacist Pharmacists deliver 
most of the time-
consuming and 
labor-intensive parts 
of HCV treatment  
S5: “I call them at two weeks to 
check up on them to see if they're 
having any side effects.  That's 
usually, usually about 10-15 
minute follow-up…I remind them... 
‘seven days from now, don't forget 
to call in your refill, to request 
it’…Then I see them at 4 weeks, 
where we do blood work, we go 
over adherence, adverse effects, 
then they go down to the lab.” 
Appreciation for 
the support that 
the pharmacist 
provides patients  
P1: “…also it looks like 
there are phone calls 
being made to make sure 
that the refills are picked 
up in a timely fashion, like 
all the things we wish 
would happen for every 
single other medication.  It 
seems like there’s that 
extra level of detail.” 
Abbreviations: CM – case manager (public health social worker); PCP – primary care provider; PCP treater – general internal  
medicine PCP trained to treat HCV; referring PCP – general internal medicine PCP who refers patients to the program 
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     (Table 3 Continued) 
Pharmacy 
Technician 
Pharmacy technician 
role is critical for 
medication access 
S5: “I have [pharmacy technician]. 
I have a patient midway through 
treatment.  Their insurance 
changed completely.  We had to 
do two different prior 
authorizations to get it approved 
for the remainder of treatment and 
we caught it right 
before…[pharmacy technician] 
called the insurance, found out the 
new insurance.  Patient didn’t 
know any of this. Probably would 
have run out of treatment before 
the PA was approved in any other 
place. But here, we have this team 
of all these people…” 
Pharmacy 
technician takes 
workload off of 
referring PCPs 
and PCP treaters 
by obtaining PA 
P5: “A prior 
authorization, which is 
huge.  And I have very 
little clue of how many 
hours that may take.  I 
know it happens, and I 
know it has to happen, 
and I know that that’s a 
central piece of the 
program.” 
 
Abbreviations: PA – prior authorization; PCP treater – general internal medicine PCP trained to treat HCV; referring PCP – 
general internal medicine PCP who refers patients to the program 
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Barriers to HCV treatment access 
 Program staff and referring PCPs identified barriers that patients face in 
accessing HCV treatment.  The most frequently cited patient-associated barriers 
were substance use, unstable and chaotic life factors, medication side effects, 
lack of motivation, poor HCV treatment literacy, and insurance access and type.  
Forgetting or not having enough time to address screening and/or treatment was 
the most recurring provider-level barrier.  Additionally, the most commonly 
identified barriers associated with the broader health care system were long 
appointment wait times and changes in insurance requirements for treatment 
approval.  Referring PCPs and program staff described how the program 
addresses and alleviates the most frequently cited barriers to HCV treatment 
access (Table 4).  
Substance use 
 The case manager and PCP treater may provide referrals to treatment 
programs and community resources for patients who wish to treat their 
substance use before initiating HCV treatment.  Some patients who are 
struggling with substance use are not ready to engage in HCV treatment, and 
these patients may miss appointments.  There are patients whose substance use 
does not preclude completing HCV treatment; the pharmacist and case manager 
may provide added support to ensure treatment adherence.   
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Unstable, chaotic lives 
 Instability and chaos enter our patients’ lives through many avenues.  
Patients express feeling overwhelmed due to stressors such as low incomes, 
lack of housing and social support, mental illness, and custody battles.  The case 
manager may support patients in a variety of psychosocial aspects, including 
helping patients access housing resources, transitional assistance, job training, 
and mental health services.  On one occasion, the case manager assisted a 
patient in handling bed bugs in his apartment.  The pharmacist describes the role 
that she and the case manager played in handling this issue and encouraging the 
patient to adhere to his Harvoni medication regimen: 
 I had a patient who I called who stopped taking his medication because his 
apartment was infested with bed bugs, and he had to throw out all of his 
furniture. Because he had to throw out all of his furniture, he was sitting on his 
bed, which was the only piece of furniture he had. He had previous lumbar injury, 
so he had severe back pain. He was in pain. He didn’t care about anything. He 
didn’t want to take his Harvoni anymore. So that’s where social work comes into 
play. I don’t have a lot of background in getting somebody furniture or getting an 
exterminator. I can help you to tell you, “no, no, no, don’t stop taking the 
medication.” And I can give you as much emotional support as possible but that 
part I don’t have the resource. So then I reach out to her [case manager] and she 
can then contact whomever. She got the patient furniture for free and got an 
exterminator coming out, and talked him [the patient] down. 
 
As portrayed in this example, the program staff work to ameliorate 
unstable situations that place a patient’s medication adherence in jeopardy. 
Medication side effects 
 Program staff and referring PCPs named medication side effects as a 
barrier to HCV treatment access in reference to IFN-based therapies, which were 
the norm before the new oral medication regimens became available.  
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Nonetheless, the pharmacist is proactive in communicating with patients about 
adverse effects of the oral, DAA medications.  She may schedule an appointment 
with the PCP treater for patients who are experiencing side effects.   
Patient lack of motivation 
 The program motivates patients to initiate and complete HCV treatment by 
frequently reaching out to and engaging patients, providing them with the 
education to take an active part in treatment decisions, and adapting outreach 
efforts to each patient’s life circumstances.  One staff member describes how the 
case manager increases patient motivation with education and engagement:  
“…the case manager, she does a lot of outreach, sort of, you know, makes sure 
people kind of stay on the evaluation pathway and keeps them contacted, does 
some education, so you know, increasing the wills in some ways.”  
Poor HCV treatment literacy 
The case manager, PCP treater, and pharmacist educate patients about 
HCV infection and the various components of HCV treatment, including 
medication adherence, adverse effects, and the program structure.  Greater 
knowledge may increase patients’ awareness of the need to be treated and of 
their own desire to do so.  One staff member explains how HCV education 
influences patients’ decisions to get treated:  “I think without the education of like 
looking into like, ’oh, this is what can happen.’  If you don’t have the education to 
kind of understand like, ‘this is what HCV is,’ I don’t think that…I think it takes a 
while maybe before it kicks in that like, ‘I want and I need to get treated.’” 
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Insurance access, type, and requirements for treatment approval 
 The case manager troubleshoots lapses in insurance coverage and other 
insurance complications.  The issue of insurance requirements for treatment 
approval is a systemic barrier and beyond the control of the program staff.  
Nonetheless, it is a program asset to have a pharmacy technician who stays 
updated on PA requirement changes for different insurances and ensures timely 
processing of PAs.   
Providers forgetting or not having enough time to address screening or treatment 
 Providers stated that although the “best practice alert” in the EHR at BMC 
increases screening rates, most patients who screen positive already have 
known risk factors, such as a history of IV drug use.  Several providers 
mentioned how they plant seeds about HCV treatment for patients who may not 
be ready to begin treatment.  One provider mentioned that she forgot to circle 
back with the patient until a few months later.  Nonetheless, the patient did 
eventually complete treatment and achieve SVR.   
Long appointment wait times 
 A shortage of specialists who treat HCV is one reason for long 
appointment wait times in specialty clinics such as gastroenterology or infectious 
disease.  PCP treaters increase the number of providers that can deliver the 
HCV care normally received in a specialty clinic.  Thus, referring PCPs believed 
that overall wait times for a patient to be assessed for HCV treatment were 
shorter in primary care than in specialty clinics.  Additionally, the proactive case 
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manager may also decrease appointment wait times by reaching out to patients 
to schedule the intake appointment in a timely manner.   
Lastly, throughout the Results section we have described a few patient 
emotions related to HCV treatment that program staff and referring PCPs 
identified as types of barriers to treatment.  Table 5 summarizes the patient 
emotions and identifies aspects of the HCV treatment program that support 
patients in each emotional state; representative quotes from interview transcripts 
are also included.   
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Table 4: The primary care hepatitis C virus (HCV) treatment program at Boston Medical Center  
(BMC) addresses barriers to HCV treatment  
 
Barriers to HCV treatment access most 
frequently cited by program staff and referring 
PCPs  
Program component or theme that addresses the barrier 
PATIENT BARRIERS  
Substance use (n=8) • Case manager role: assesses and addresses psychosocial needs, 
including prior and current substance use; provides additional 
support during HCV treatment process 
• PCP treater role: assesses prior and current substance use and 
may make treatment recommendations 
• Pharmacist role: provides additional support to ensure medication 
adherence  
• Program theme: personalized medicine 
Unstable, chaotic lives (n=7) • Case manager role: assesses and addresses psychosocial needs 
• Pharmacist role: tailors medication adherence strategies to 
patients’ specific needs 
• Program theme: personalized medicine 
• Program theme: high patient engagement 
• Program theme: patient empowerment through education 
Medication side effects (n=4) • This barrier was cited in regards to IFN-based therapies, not DAA 
medications.   
• Pharmacist role: regularly assesses medication adverse effects 
Patient lack of motivation (n=3) • Program theme: personalized medicine 
• Program theme: high patient engagement 
• Program theme: patient empowerment through education 
Abbreviations: Case manager – public health social worker; DAA – direct-acting antivirals; IFN – interferon; PCP – primary care  
provider; PCP treater – general internal medicine PCP trained to treat HCV 
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(Table 4 Continued) 
Poor HCV treatment literacy (n=3) • Case manager role: educates patient about HCV and the HCV 
treatment program  
• Pharmacist role: educates patient about medication regimen 
• Program theme: personalized medicine 
• Program theme: patient empowerment through education 
• Program theme: high patient engagement 
Insurance – access and type (n=3) • Case manager role: troubleshoots insurance coverage issues 
PROVIDER BARRIERS  
Forgetting or not having enough time to address 
screening or treatment (n=3) 
• Program component: “best practice alert” in EHR 
SYSTEM BARRIERS  
Long appointment wait time (n=6) • PCP treater role: increases number of health professionals who 
treat HCV and thus makes treatment more readily available 
• Program theme: efficiency 
Insurance requirements and changes in 
requirements for treatment approval (n=4) 
• Pharmacy technician role: obtains PA and appeals if request 
denied 
Abbreviations: Case manager – public health social worker; EHR – electronic health record; PA – prior authorization; PCP – 
primary care provider; PCP treater: general internal medicine PCP trained to treat HCV 
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Table 5: The primary care hepatitis C virus (HCV) treatment program at Boston Medical Center (BMC) responds to  
patient emotions associated with the HCV treatment process 
Patient emotion Example from interview 
transcript 
Program theme that 
responds to patient 
emotion 
Example from interview 
transcript 
Discomfort and 
anxiety about HCV 
treatment process 
S2: “There’s been other cases 
where, you know, patients who 
have abused IV drugs in the 
past, you know, we have to get 
labs or blood drawn at 4 weeks 
and at the end of treatment to 
make sure medication's 
working.  And I think a lot, some 
patients will feel uncomfortable 
with getting stuck by a needle 
and having their labs drawn 
again...” 
 
 
Personalized medicine: 
Accommodation of treatment 
access to patient’s physical, 
social, and emotional 
environments 
S2: “…just like making sure the 
patient goes to the pharmacy and 
picks up their medicine, or making 
sure they go to the lab and get their 
labs drawn. I don’t want to say 
handholding, but I think just kind of 
walking them through the process 
of these steps. Or you know, even 
like they get nervous about knowing 
where the pharmacy is, walking 
them directly to the pharmacy.  Or 
they might have a refill on 
something else at the same time 
and getting everything together.  
Just kind of making the process 
smooth and facilitate it.”  
Apprehension 
about engaging 
with new health 
professionals 
 
S2: “…he just felt 
uncomfortable meeting 
providers and people he’s 
never met before.” 
 
 
High patient engagement: 
Warm handoff 
P3: “Well the flow is easier because 
it’s just down the hall.  So it’s 
essentially, it’s a hand-off more than 
it is a referral and they’ll get to you 
when they get to you in X number of 
months.”   
 
Efficiency: Smoother referral 
process due to proximity of 
program to primary care  
P4: “I think for the patients it’s better 
to do it in primary care if possible, 
because it’s just another barrier to 
go to a new place where they may 
not know people.” 
 
Abbreviations: IV – intravenous 
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(Table 5 Continued) 
Feeling 
overwhelmed at 
prospect of HCV 
treatment due to 
other psychosocial 
factors 
P1: “…sometimes I see patients 
through times when their lives 
are like, even for chaotic lives, 
like especially difficult.  Like you 
know, if I see a patient and he 
says, ‘last week I woke up and 
my girlfriend was dead of an 
overdose on the bed beside 
me’, like I’m thinking of, I’m not 
going to say ‘Let’s refer you for 
HCV treatment.’”  
Personalized medicine: 
Accommodation of treatment 
access to patient’s physical, 
social, and emotional 
environments 
S3: “…she has a lot of other social 
things going on. She has her son, 
for instance, is right now actively 
using and she’s very concerned 
about that. She has two other kids 
that are in school. They’re doing 
great but she has some depression 
and some other stressors that need 
to be addressed and we want to 
make sure that we have a holistic 
approach to care so that she can 
successfully complete HCV 
[treatment] so she continues to be 
healthy.” 
Worry P1: “…it is true in a lot of 
people, even if they aren’t 
necessarily bringing it up, that if 
you really ask them, they will be 
very worried about HCV.” 
High patient engagement: 
Time investment when 
meeting with patients 
S3: “She was very appreciative of 
like, the social worker, because she 
was comfortable talking with her, 
she understood it and that she was 
going to be an added support 
throughout this journey.”  
 
Stress about HCV 
treatment with IFN-
based therapies 
and their severe 
side effects 
P4: “Yea, so the older, the 
people I would say who are in 
their fifties, sixties, seventies 
who have it, all know people 
who suffered or they 
themselves suffered through 
the treatment, so I’ve definitely, 
when I bring it up, they like 
jump to the ceiling and I have to 
talk them off the ceiling.  I 
mean, they really have PTSD 
from these treatments.”  
Patient empowerment 
through education: 
Education about DAAs in 
contrast to IFN-based 
therapies 
P4: “So I definitely have to do that 
[educate patients].  For people who 
are really knowledgeable and have 
peers, but actually aren’t 
knowledgeable about the new 
treatments, and they’re like 
converting now.  Like now, you 
know, people are, you know, 
they’ve seen the light, they’re 
converted.” 
 
 
Abbreviations: DAA – direct-acting antiviral; IFN – interferon; PTSD – post-traumatic stress disorder
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DISCUSSION  
 
In this study, we gained a deeper understanding of the workings of a 
primary care HCV treatment program in an urban, safety-net hospital.  We found 
that two roles in particular are critical for the success of the program: the case 
manager, who is a public health social worker, and the pharmacist.  The public 
health social worker plays an integral role in linking patients to care and 
facilitating their progression through the complex HCV treatment process with its 
multiple appointments, imaging and lab tests, and trips to the pharmacy.  
Additionally, the social worker eases the burden of HCV treatment by addressing 
psychosocial factors.  The pharmacist also plays a crucial role by ensuring 
treatment adherence through medication administration teaching, medication 
refill reminders, and follow-up appointments for lab tests.   
The pharmacist and pharmacy technician work together to obtain PAs for 
prescribed agents and to address lapses in insurance coverage of medications.  
Staff members in the HCV treatment program work at the “top of their license,” 
meaning they complete the most complex tasks that their licenses allow.  As a 
result, work is off-loaded from clinicians and allows clinicians to focus on direct 
patient care.  We also identified several themes from interviews with staff and 
referring PCPs that describe HCV treatment delivery in the program: efficiency, 
clear and open communication, personalized medicine, high patient engagement, 
and patient empowerment through education.  
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Although DAA therapies have increased HCV treatment efficacy, hurdles 
to attaining HCV eradication remain.79  Overall, program staff and referring PCPs 
identified barriers to HCV treatment access that are similar to barriers present 
since the late 1990s, when IFN-based HCV treatment first became available.  
However, the types of barriers at the forefront in the DAA era may differ from the 
most common barriers in the IFN era.  For example, HCV treatment programs 
analyzed in the IFN era noted medication side effects as a major barrier to 
treatment access.  Although medication side effects are still a concern with DAA 
therapies, they are not as significant.  The most frequently identified patient-
associated barriers to treatment in our study were substance use and unstable 
and chaotic life factors.  
Additionally, inadequate patient literacy in HCV treatment options and 
processes may be a more significant barrier with the advent of DAA medications.  
As our study identified, patients do not always know the difference in treatment 
processes between IFN-based and DAA regimens.  Patients may perceive 
treatment prospects negatively if they associate the process with IFN side 
effects.  As a result, they may be less likely to take advantage of the improved 
DAA medications.  Greater knowledge about HCV and treatment processes has 
been shown to encourage treatment considerations.47  Thus, poor literacy in HCV 
treatment may be a crucial barrier to address in the DAA era.  
High costs of DAA medications have pushed the barriers of insurance 
coverage and PA attainment to the forefront.79  One of the assets of the HCV 
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treatment program at BMC is that the pharmacy technician is able to stay current 
in insurance coverage requirement changes and PA processes.  Health care 
settings that deliver HCV treatment in the DAA era may need to adjust their 
processes to address insurance coverage barriers.   
Program staff and referring PCPs also identified patient emotions 
associated with the HCV treatment process that have been previously studied, 
such as discomfort and anxiety at the prospect of treatment and general worry 
about a HCV diagnosis.80,81,82  Support during the treatment process, either from 
family, friends, or health care providers, is beneficial for treatment adherence, 
and other studies have also described its importance.80,81,82  The staff in the HCV 
treatment program address patients’ emotions by filling a niche of support, which 
may be especially pertinent for our vulnerable patient population with limited 
sources of assistance and encouragement.  Some factors affecting patients’ 
emotions towards treatment may be specific to the patient population at BMC, 
such as past IV drug use or overwhelming chaotic life factors.  Nonetheless, we 
believe patients’ emotions may be generalizable to patient populations at other 
safety-net hospital settings.  
Social workers and pharmacists may be uniquely positioned to address 
barriers that are at the forefront of HCV treatment access in the era of DAA 
medications and to provide emotional support.  Also, patients who previously 
would not be considered good candidates for treatment are now eligible with 
simpler treatment regimens.   For example, we can treat through some 
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substance use, although at the risk of non-adherence and reinfection.  The social 
worker and pharmacist in the HCV treatment program at BMC provide extra 
support that makes it more feasible to treat high-risk patients.   
The HCV treatment program public health social worker brings expertise 
in population management and community resources to the position.  One study 
conducted qualitative in-depth interviews with participants who had undergone 
HCV treatment in the United Kingdom and found multiple opportunities for social 
work involvement.45  First, social workers are well positioned to increase HCV 
diagnosis rates due to their wide range of client groups, including high-risk clients 
who may be incarcerated, homeless, or current or former IDUs.  Social workers 
may begin discussions about HCV testing and treatment with clients who 
disclose certain risk factors.45  Second, strong relationships between social 
workers and medical staff may efficiently link clients to HCV care.  Third, social 
workers may support patients by providing information about HCV and assisting 
with various psychosocial needs, such as substance use treatment, treatment 
literacy, and insurance enrollment.  Social workers’ training in providing holistic 
social and emotional support, as well as in addressing inequalities and navigating 
systems, lends itself well to increasing HCV treatment access.45   Thus, an 
advantage of receiving care in the HCV treatment program at BMC is that it 
automatically provides patients with a public health social worker. 
Collaboration between social workers and pharmacists in the context of 
primary care, as seen in the HCV treatment program, is also advantageous for 
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the quality and delivery of HCV treatment.83  The collaboration brings together 
pharmacists’ expertise in medication use and social workers’ training in 
psychological, social, and environmental evaluations.83  Pharmacists and social 
workers have complementary strengths that, when applied to medication 
management, can improve health outcomes such as medication adherence.  
Social workers rely on pharmacists when handling medicine-related issues with 
patients, and pharmacists can depend on social workers when they identify 
psychosocial issues.83        
The expansion of the pharmacist’s role into primary care and HCV 
treatment is especially relevant as the United States is projected to face a 
shortfall of 14,900-35,600 PCPs by 2025.84  Simultaneously, chronic diseases 
are prevalent in the United States population,39 and medications are playing a 
more significant role in the prevention and management of chronic diseases 
within primary care.85  Additionally, shorter hospital stays and more outpatient 
surgeries result in patients relying on primary care for more intensive medication 
therapy.85  The increasingly complex medication treatment regimens require 
more oversight of adverse effects.   
Pharmacists may be able to fill much-needed roles in primary care and on 
multidisciplinary teams.  The role of the pharmacist is essential to the primary 
care HCV treatment program at BMC, especially in the guidance that the 
pharmacist provides patients in adhering to the HCV treatment medication 
regimen.  The pharmacist’s role is in accordance with the American Society of 
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Health-System Pharmacists’ Pharmacy Practice Model Initiative (PPMI).  The 
PPMI’s goal is to expand the health-system pharmacy practice and transition to a 
patient-centered care model in order to increase quality and continuity of care.86  
Specifically, pharmacists are moving away from filling prescriptions and 
preparing products for distribution and towards medication therapy 
management.87  The pharmacist administers patient visits that otherwise PCP 
treaters may conduct in other clinical settings.  The pharmacist thus increases 
access to HCV treatment services and provides needed medication management 
support for patients. 
The change in the role of the pharmacist, namely increased direct patient 
care, relies on an expansion of the pharmacy technician role.86,87  Pharmacy 
technicians became critical resources in the early 2000s during a pharmacist 
shortage, and their roles have continued to broaden.  Pharmacy technicians are 
responsible for entering medication orders, dispensing prescriptions, and 
managing medication inventories.88  Pharmacy technicians are increasingly 
taking on medication safety and quality assurance and compiling medication lists, 
among other tasks.88  Despite the variation in pharmacy technician 
responsibilities and training across the United States,89 most pharmacy 
technicians today also communicate with insurance companies for medication 
approvals and complete necessary paperwork.90  
The pharmacy technician completes tasks in the HCV treatment program 
that may otherwise be completed by PCPs or pharmacists, and thus frees up 
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PCP treaters’ and the pharmacist’s time for direct patient care.  For example, the 
time-consuming and labor-intensive process of obtaining prior authorizations 
requires the pharmacy technician to submit necessary forms, medical records, 
and test results for approval to the patient’s insurance company.91  In other care 
models, the pharmacist or PCP may be responsible for this process, but in the 
HCV treatment program they are able to focus on patient care while the 
pharmacy technician obtains the PA.  
Limitations 
Our study has several limitations.  First, we assessed patient viewpoints 
through the lens of third parties such as program staff and referring PCPs.    
Second, the PCPs who agreed to participate in the study may not be 
representative of all PCPs; they may be more likely to have an interest in HCV.  
They may be more informed about HCV infection and care protocols, have a 
greater awareness of the program and its functions, and thus engage with the 
program in more depth.  Indeed, several of the referring PCPs who were 
interviewed have a strong background in substance use and addiction medicine.  
This background may have skewed their viewpoints and experiences in favor of 
the program.      
 A third limitation of our study includes bias in the staff interviews since the 
staff were describing their own work.  They may have been less likely to criticize 
their efforts in implementing the program.  Additionally, interview coding may be 
subjective.  Qualitative methods limit our ability to estimate the frequency of each 
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identified barrier to HCV treatment access, or the relative importance of each 
defined program theme.  Lastly, this program addresses the needs of an urban, 
safety-net hospital and its diverse, primarily low-income patient population.  
Although program aspects may be generalizable to other safety-net hospitals, 
they may not be generalizable to other clinical settings and patient populations.  
Implications 
 
This study shows that the HCV treatment program at BMC has promise to 
deliver HCV treatment to an urban, underserved patient population.  Barriers to 
treatment accessibility in the DAA era may be more centered on poor patient 
treatment literacy, psychosocial factors, and insurance coverage as opposed to 
medication side effects like during the IFN era.  Public health social workers and 
pharmacists may be particularly valuable resources in supporting patients 
through the treatment process and providing medication management in the era 
of DAA medications.  Further study of the program’s efficacy in improving HCV 
outcomes is warranted. 
 
 
 
 
  
! 56 
CONCLUSIONS 
In summary, we described a pharmacist-managed primary care-based 
HCV treatment program at an urban, safety-net hospital patient-centered medical 
home in the era of DAA medications.  We conducted semi-structured interviews 
with program staff members and general internal medicine PCPs who refer 
patients to the program, and identified themes from interview transcripts through 
qualitative analysis.  Five themes characterize the program’s successful HCV 
treatment delivery: efficiency, clear and open communication, personalized 
medicine, high patient engagement, and patient empowerment through 
education.  The pharmacist and public health social worker have key roles in 
supporting patients in medication management and psychosocial factors 
respectively.  The pharmacy and social work fields may be uniquely positioned to 
increase HCV treatment access in the DAA era, especially when specialist and 
primary care fields are overburdened by high demand.   
We are unaware of other pharmacist-managed, primary care-based HCV 
treatment models in which DAA medications have been the exclusive prescribing 
agents and a public health social worker provides patient navigation.  Further 
study of the program’s efficacy in improving HCV outcomes is warranted. 
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APPENDIX A: Program Staff Study Recruitment Email 
 
 
Dear [Subject], 
  
My name is [Research Assistant].  I am a [degree] student at the [school] working 
with [Principal Investigator]. We are conducting interviews as part of a research 
study designed to increase our understanding of the budgetary impact of the 
Hepatitis C treatment program in General Internal Medicine at Boston Medical 
Center.  As a member of the treatment program staff you are uniquely positioned 
to offer valuable information about the program.  Your responses will allow our 
research staff to gauge the fiscal impact of the program as well as barriers and 
facilitators to its overall success. Information gained from our research will both 
help to improve the program at BMC and disseminate it elsewhere.   
 
The interview process will be informal and should take about 30-60 minutes of 
your time.  Your responses will be kept confidential and be de-identified in order 
to ensure anonymity throughout the data collection and analysis process.  As a 
thank you, we will compensate you with a $25 gift card for your participation.   
 
We hope that you will be willing to participate in our study.  If so, please suggest 
some days and times I could meet with you.  Thank you for your consideration,      
 
Best regards,  
 
[Research Assistant] 
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APPENDIX B: PCP Study Recruitment Email 
 
 
 
Dear [Subject],  
 
My name is [Principal Investigator] and I am reaching out because my team and I 
are conducting interviews as part of a research study to increase our 
understanding of the processes involved in Hepatitis C (HCV) treatment here at 
BMC.  As a primary care provider, you are uniquely positioned to offer insights 
about the screening, referral, and follow-up processes for HCV treatment within 
your department, as well as to offer a perspective about factors that either assist 
or prevent patients from accessing care.  Information gained from our research 
will help us understand best practices for screening and treating patients with 
HCV in primary care settings.  
 
I would like to invite you to participate in a short (30 minute) interview with our 
research assistant, [name].  Your responses will be kept confidential and will be 
de-identified to ensure anonymity.  You will receive a $25 gift card for your 
participation.    
 
We hope that you will be able to participate in our study.  Your knowledge and 
insights are invaluable.  If you are able to participate, please suggest some days 
and times when you could participate in the interview.  Thank you in advance for 
your consideration.   
 
Sincerely,  
 
[Principal Investigator] 
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APPENDIX C: Program Staff Interview Guide 
 
Hepatitis C (HCV) Treatment Program Budget Impact Analysis (BIA) 
Interview Guide - Practice Staff 
 
Research Question - Interview questions are designed to engage with and probe 
subjects (project staff and patients) for perceived impacts of the HCV treatment 
program.  Specifically, we would like to assess barriers and facilitators to 
program implementation, direct costs of program components, as well as 
changes in staffing and utilization of resources, which result from program 
implementation.   
 
Practice Staff Interview – (medical director, HCV provider, case manager, 
pharmacy technician, pharmacist, practice manager) 
 
Framing prompt:  
I am going to ask you some questions about your experiences with the BMC 
Hepatitis C program.  We are interested in hearing your thoughts about the 
program, its effectiveness, and particularly your opinions of various program 
components.  There are no right or wrong answers and your responses will be 
anonymous and kept in strict confidentiality.   However, because you are the only 
(medical director, care manager, pharmacy technician, pharmacist) in the 
program it is possible that some things you say could be associated with you.  
With that in mind, please let me know if there are any questions you would prefer 
not to answer. 
 
1. Can you tell me a bit about your professional background, and your role in the 
hepatitis C treatment program?   
 
2. Where did you complete your (staff specific) training? Prior to the initiation of 
the program did you have any specialized training in treating HCV patients?  
What was the timing / duration of this training?  Who paid for you to do the 
training?   
 
3. I would like you to think back to the most recent patient (case) you can recall 
treating (interacting with) in the HCV program. Can you tell me a bit about this 
experience and how your role in the program fit into the overall patient treatment 
process?   
 
4. Can you describe any changes in access to Hepatitis C treatment for patients 
you have noticed during your time in the program?   
 
5. Were you a part of the care team before the program was implemented, and if 
so in what ways have care processes changed since the program began?  
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6. What changes have you noticed in levels of demand for care?  
 
7. What changes have you noticed in the time necessary to treat patients 
receiving the care intervention?   
 
8. I would like you to think back to before the program was initiated at BMC up to 
now (or since the program started, if interviewee indicated s/he did not work at 
BMC before that).  In your experience, what if any have been the greatest 
changes in cost(s) associated with treatment or patient management that you 
have seen since your time in the program? 
 
***Probes - These cost changes could relate to:  Key points from answers 
to preceding questions will guide probes to cost questions.  For example, if 
staffing changes what are the implications for costs?  If any changes in 
care process, what are the implications for cost?  Additionally, we are 
interested in: 
• Changes in staffing such as hiring additional personnel and / or shift 
changes 
• Increased or decreased utilization of technology  
• Costs associated with additional patient appointments or length of patient 
visits   
9. Thinking about your time in the program, what do you think are the best 
strategies to promote HCV treatment in primary care?   
 
10. What challenges to care delivery have you observed?  How did you or others 
address these?   
 
11. What do you feel have been the greatest barriers to the success of the 
program? 
 
12. What have been the greatest facilitators of program success?    
 
13. Is there anything else you would like to share about the program?   
 
Demographic Questions  
***Note interviewee gender 
14. What is your D.O.B? 
 
15. Which racial or ethnic group do you identify with?  
 
16. Do you speak any non-English languages without the use of an interpreter? 
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17. How many years have you been practicing, working, etc.?  
 
18.  In order to complete the BIA we need to have an estimate (within 5-10k / yr.) 
of your yearly salary.  Would you mind providing me with that information?   
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APPENDIX D: PCP Interview Guide 
 
Framing Prompt:  Thank you for taking the time to talk with me.  I have several 
questions for you about the process of treating patients with HCV in your 
department.  I wanted to talk to you because you have been at BMC for a 
number of years, and could describe to me how HCV treatment has changed 
over the past few years. There are no right or wrong answers and your 
responses will be anonymous and kept in strict confidentiality.  If there are any 
questions that you prefer not to answer, please tell me and we can move on to 
the next question.  
  
1) First, can you take me through the step by step process of how your patients 
accessed HCV treatment before the implementation of the HCV treatment 
program in primary care, starting when you first became aware of the 
diagnosis? 
Probes: 
• What prompted you to screen your patients for HCV?   
• Can you describe the referral process that was in place then? (Which 
patients?  To which specialists?) 
• What barriers to HCV treatment were present at that time? 
o Patient factors – Social, economic, and physical environments?  
Logistics of transportation and housing?  Medication side effects?  
Substance use as related to HCV treatment?  What substance use 
treatment programs were available to your patients?  Missed 
appointments? 
o Provider factors – Difficulty remembering to screen or having time 
to screen?  Did you have time to assess/address HCV infection? 
Did the specialist require patient abstinence for HCV treatment?   
o Systems factors – Referral was placed but appointment not 
scheduled?  Wait time to get specialty appointment? 
• Can you estimate the time frame from when the referral was made to 
when treatment was begun? 
• Were you satisfied with your patients’ ability to access treatment and the 
quality of treatment received? 
 
2)  Since the HCV treatment program was implemented in primary care, how has 
the screening and referral process for HCV treatment changed?  
Probes: 
• Has the “best practice alert” changed how many patients you refer for 
treatment? 
• How do the different team members (case manager, pharmacy technician, 
and pharmacist) support you/the care of your HCV infected patients? 
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3) How has the primary care HCV program helped to address patient, provider, 
and system barriers? 
Probes: 
• Do you rely on other staff members to help you follow up with patients? 
• Has the time frame from when the referral is made to when treatment is 
begun changed? 
• Are you satisfied with your patients’ ability to access treatment and its 
quality? 
 
4) What are some barriers that remain to having patients engage in treatment? 
Probes:  
• Substance use as related to HCV treatment?  Missed appointments? 
 
5) Can you give me an example of a recent patient that you referred to the HCV 
treatment program?  Can you tell me a little bit about this experience, from 
learning of the patient’s HCV diagnosis to going through the referral process? 
 
6) Is there anything else you would like to share about your experience in getting 
your patients HCV treatment? 
 
Demographic Questions: 
 
7) How many years have you been practicing medicine, including residency? 
 
8) Which best describes your race? 
• White 
• Black or African American 
• American Indian or Alaska Native 
• Asian 
• Native Hawaiian or Other Pacific Islander 
• Other Race: 
 
9) Do you speak any non-English languages without the use of an interpreter? 
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